Hypocretin/Orexin Replacement Therapy in Hypocretin/Orexin-Deficient Narcolepsy: An Overview

Contemporary Clinical Neuroscience

Volumn , Issue , 2005, Pages 367-388

  Fujiki, Nobuhiro ^a,b   Nishino, Seiji ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Canine Narcolepsy; Human Narcolepsy; Hypocretin Level; Hypocretin Neuron; Isolate Sleep Paralysis

Indexed keywords

EID: 85145672227     PISSN: 2627535X     EISSN: 26275341     Source Type: Book Series    
DOI: 10.1385/1-59259-950-8:367     Document Type: Chapter

References (139)

1. Lin, L., Faraco, J., Li, R., et al. (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365–376.
2. Chemelli, R.M., Willie, J., Sinton, C., et al. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437–451.
3. Nishino, S., Ripley, B., Overeem, S., et al. (2001) Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. 50, 381–388.
4. Nishino, S., Ripley, B., Overeem, S., Lammers, G.J., and Mignot, E. (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39–40.
5. Mignot, E., Lammers, G.J., Ripley, B., et al. (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553–1562.
6. Honda,Y. (1988) Clinical features of narcolepsy, in HLA in narcolepsy (Honda, Y. and Juji, T., eds.) Springer-Verlag, Berlin, pp. 24–57.
7. Riehl, J., Nishino, S., Cederberg, R., Dement, W.C., and Mignot, E. (1998) Development of cataplexy in genetically narcoleptic Dobermans. Exp. Neurol. 152, 292–302.
8. Hara, J., Beuckmann, C.T., Nambu, T., et al. (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30, 345–354.
9. Owens, D.R., Zinman, B., Bolli, G.B. (2001) Insulins today and beyond. Lancet 358, 739–746.
10. Jenner, P. (2003) Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson’s disease. Curr. Opin. Neurol. 16(suppl 1), S3–S7.
11. Nishino, S., Okura, M., and Mignot, E. (2000) Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med. Rev. 4, 57–99.
12. de Rijk, M.C., Tzourio, C., Breteler, M.M., et al. (1997) Prevalence of Parkinsonism and Parkinson’s disease in Europe: the Europarkinson collaborative study. European community concerted action on the epidemiology of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 62, 10–15.
13. Shepherd, D.I. and Summers, A. (1996) Prevalence of multiple sclerosis in Rochdale. J. Neurol. Neurosurg.Psychiatry 61, 415–417.
14. Broughton, R., Dunham, W., Newman, J., Lutley, K., Dushesne, P., and Rivers, M. (1988) Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroenceph. Clin. Neurophysiol. 70, 473–481.
15. Aldrich, M.S., Chervin, R.D., and Malow, B.A. (1997) Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 20, 620–629.
16. Fukuda, K., Miyasita, A., Inugami, M., and Ishihara, K. (1987) High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan. Sleep 10, 279–286.
17. Takeuchi, T., Miyasita, A., Sasaki, Y., Inugami, M., and Fukuda, K. (1992) Isolated sleep paralysis elicited by sleep interruption. Sleep 15, 217–225.
18. Thannickal, T.C., Moore, R.Y., Nienhuis, R., et al. (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469–474.
19. Peyron, C., Faraco, J., Rogers, W., et al. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991–997.
20. de Lecea, L., Kilduff, T.S., Peyron, C., et al. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U S A 95, 322–327.
21. Sakurai, T., Amemiya, A., Ishil, M., et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573–585.
22. Sakurai, T. (2002) Roles of orexins in regulation of feeding and wakefulness. Neuroreport 13, 987–95.
23. Ripley, B., Fujiki, N., Okura, M., Mignot, E., and Nishino, S. (2001) Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol. Dis. 8, 525–534.
24. Willie, J.T., Chemelli, R.M., Sinton, C.M., et al. (2003) Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 38, 715–730.
25. Willie, J.T., Chemelli, R.M., Sinton, C.M., and Yanagisawa, M. (2001) To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci. 24, 429–458.
26. Kisanuki, Y.Y., Chemelli, R.M., Tokita, S., Willie, J.T., Sinton, C.M., and Yanagisawa, M. (2000) The role of orexin receptor (OX1R) in the regulation of sleep. Sleep 23, A91.
27. Nishino, S. and Mignot, E. (1997) Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. 52, 27–78.
28. Mignot, E. (2000) Pathophysiology of Narcolepsy, in Principles and Practice of Sleep Medicine (Kryger, M.H., Roth, T., Dement, W.C., and Roth, T., eds.) WB Saunders, Philadelphia, pp. 663–675.
29. Mitler, M.M., Aldrich, M.S., Koob, G.F., and Zarcone, V.P. (1994) Narcolepsy and its treatment with stimulants. Sleep 17, 352–371.
30. Nishino, S., Mao, J., Sampathkumaran, R., Shelton, J., and Mignot, E. (1998) Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res. Online 1, 49–61. http://www.sro.org/1998/Nishino/49/.
31. Wisor, J.P., Nishino, S., Sora, I., Uhl, G.H., Mignot, E., and Edgar, D.M. (2001) Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 21, 1787–1794.
32. Babcock, D.A., Narver, E.L., Dement, W.C., and Mitler, M.M. (1976) Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol. Biochem. Behav. 5, 599–602.
33. Foutz, A.S., Delashaw, J.B., Guilleminault, C., and Dement, W.C. (1981) Monoaminergic mechanisms and experimental cataplexy. Ann. Neurol. 10, 369–376.
34. Yamanaka, A., Beuckmann, C.T., Willie, J.T., et al. (2003) Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38, 701–713.
35. Yamanaka, A., Tsujino, N., Funahashi, H., et al. (2002) Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Commun. 290, 1237–1245.
36. Kiyashchenko, L.I., Mileykovskiy, B.Y., Lai, Y.Y., and Siegel, J.M. (2001) Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J. Neurophysiol. 85, 2008–2016.
37. Nambu, T., Sakurai, T., Mizukami, K., Hosoya, Y., Yanagisawa, M., and Goto, K. (1999) Distribution of orexin neurons in the adult rat brain. Brain Res. 827, 243–260.
38. Peyron, C., Tighe, D.K., van den Pol, A.N., et al. (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996–10015.
39. Hagan, J.J., Leslie, R.A., Patel, S., et al. (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. U S A 96, 10911–10916.
40. Horvath, T.L., Peyron, C., Diano, S., et al. (1999) Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J. Comp. Neurol. 415, 145–159.
41. Taheri, S., Zeitzer, J.M., and Mignot, E. (2002) The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu. Rev. Neurosci. 25, 283–313.
42. Nishino, S., Fujiki, N., Ripley, B., et al. (2001) Decreased brain histamine contents in hypocretin/ orexin receptor-2 mutated narcoleptic dogs. Neurosci. Lett. 313, 125–128.
43. Mieda, M., Willie, J.T., Hara, J., Sinton, C.M., Sakurai, T., and Yanagisawa, M. (2004) Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc. Natl. Acad. Sci. U S A 101, 4649–4654.
44. Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Efficient selection for high-expression trans-fectants with a novel eukaryotic vector. Gene 108, 193–199.
45. Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E., and Nishino, S. (2003) Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26, 953–959.
46. Tonokura, M., Fujita, K., Morozumi, M., Yoshida, Y., Kanbayashi, T., and Nishino, S. (2003) Narcolepsy in a hypocretin/orexin-deficient chihuahua. Vet. Rec. 152, 776–779.
47. Schatzberg, S.J., Cutter-Schatzberg, K., Nydam, D., et al. (2004) The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J. Vet. Intern. Med. 18, 586–568.
48. Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A., and Dement, W.C. (1988) Effect of alpha 1-adrenoceptors blockade with prazosin in canine narcolepsy. Brain Res. 444, 184–188.
49. Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A., and Dement, W.C. (1988) Role of central alpha-1 adrenoceptors in canine narcolepsy. J. Clin. Invest. 82, 885–894.
50. Nishino, S., Haak, L., Shepherd, H., et al. (1990) Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep. J. Pharmacol. Exp. Ther. 253, 1145–1152.
51. Nishino, S., Arrigoni, J., Shelton, J., Dement, W.C., and Mignot, E. (1993) Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 16, 706–712.
52. Nishino S., Fruhstorfer, B., Arrigoni, J., Guilleminault, C., Dement, W.C., and Mignot, E. (1993) Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J. Pharmacol. Exp. Ther. 264, 1079–1084.
53. Nishino, S., Shelton, J., Renaud, A., Dement, W.C., and Mignot, E. (1995) Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy. J. Pharmacol. Exp. Ther. 1995; 272, 1170–1175.
54. Reid, M.S., Tafti, M., Geary, J.N., et al. (1994) Cholinergic mechanisms in canine narcolepsy— I. Modulation of cataplexy via local drug administration into the pontine reticular formation. Neuroscience 59, 511–522.
55. Reid, M.S., Tafti, M., Nishino, S., Sampathkumaran, R., Siegel, J.M., and Mignot, E. (1996) Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Res. 733, 83–100.
56. Shelton, J., Nishino, S., Vaught, J., Dement, W.C., and Mignot, E. (1995) Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 18, 817–826.
57. John, J., Wu, M.F., and Siegel, J.M. (2000) Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res. Online 3, 23–28.
58. Kodama, T. and Kimura, M. (2002) Arousal effects of orexin—A correlate with GLU release from the locus coeruleus in rats. Peptides 23, 1673–1681.
59. Thannickal, T.C., Siegel, J.M., Nienhuis, R., and Moore, R.Y. (2003) Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol. 13, 340–351.
60. Arii, J., Kanbayashi, T., Tanabe, Y., et al. (2004) CSF hypocretin-1 (orexin-A) levels in children with neurologic and sleep disorders. Neurology 63, 2440–2442..
61. Nishino, S., Kanbayashi, T., Fujiki, N., et al. (2003) CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 61, 823–825.
62. Kanbayashi, T., Ishiguro, H., Aizawa, R., et al. (2002) Hypocretin-1 (orexin-A) concentrations in cerebrospinal fluid are low in patients with Guillain-Barre syndrome. Psychiatry Clin. Neurosci. 56, 273–274.
63. Ripley B., Overeem, S., Fujiki, N., et al. (2001) CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 57, 2253–2258.
64. Kubota, H., Kanbayashi, T., Tanabe, Y., Takanashi, J., and Kohno, Y. (2002) A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid. J. Child Neurol. 17, 537–539.
65. Kato, T., Kanbayashi, T., Yamamoto, K., et al. (2003) Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern. Med. 42, 743–745.
66. Laterra, J., and Goldstein, G.W. (1996) Ventricular organization of cerebrospinal fluid: blood–brain barrier, brain edema, and hydrocephalus, in Principles of Neural Science (Kandel, E.R., Schwartz, J.H., and Jessell, T.M., eds.) McGraw-Hill, New York.
67. Johanson, C.E. (1995) Ventricles and cerebrospinal fluid, in: Neuroscience In Medicine (P.M. C, ed.) JB Lippincott, Philadelphia, pp.171–196.
68. Brightman, M.W. (1977) Morphology of blood–brain interfaces. Exp. Eye Res. 25(suppl), 1–25.
69. Begley, D.J. and Brightman, M.W. (2003) Structural and functional aspects of the blood-brain barrier. Prog. Drug Res. 61, 39–78.
70. Pardridge, W.M. (1995) Transport of small molecules through the blood–brain barrier: biology and methodology. Adv. Drug Deliv. Rev. 15, 5–36.
71. Prokai-Tatrai, K. and Prokai, L. (2003) Modifying peptide properties by prodrug design for enhanced transport into the CNS. Prog. Drug Res. 61, 155–188.
72. Grondin, R., Zhang, Z., Ai, Y., Gash, D.M., and Gerhardt, G.A. (2003) Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog. Drug Res. 61, 101–123.
73. Kastin, A.J. and Akerstrom, V. (1999) Orexin, A. but not orexin B rapidly enters brain from blood by simple diffusion. J. Pharmacol. Exp. Ther. 289, 219–223.
74. Yoshida, Y., Fujiki, N., Maki, R.A., Schwarz, D., and Nishino, S. (2003) Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci. Lett. 346, 182–186.
75. Prokai L. (1998) Peptide drug delivery into the central nervous system. Prog. Drug Res. 51, 95–131.
76. Kawai, M., Fukuta, N., Ito, N., et al. (1990) Preparation and opioid activities of N-methylated analogs of [D-Ala2,Leu5]enkephalin. Int. J. Pept. Protein Res. 35, 452–459.
77. Witt, K.A., Slate, C.A., Egleton, R.D., et al. (2000) Assessment of stereoselectivity of trimethylphenylalanine analogues of delta-opioid [D-Pen(2),D-Pen(5)]-enkephalin. J. Neurochem 75, 424–435.
78. Gentry, C.L., Egleton, R.D., Gillespie, T., et al. (1999) The effect of halogenation on blood–brain barrier permeability of a novel peptide drug. Peptides 20, 1229–1238.
79. Weber S.J., Greene, D.L., Sharma, S.D., et al. (1991) Distribution and analgesia of [3H][D-Pen2, D-Pen5]enkephalin and two halogenated analogs after intravenous administration. J Pharmacol Exp Ther 259, 1109–1117.
80. Delaet, N.G., Verheyden, P., Velkeniers, B., et al. (1993) Synthesis, biological activity and con-formational study of a somatostatin hexapeptide analogue containing a reduced peptide bond. Pept. Res. 6, 24–30.
81. Wong, A. and Toth, I. (2001) Lipid, sugar and liposaccharide based delivery systems. Curr. Med. Chem. 8, 1123–1136.
82. Polt, R. and Palian, M.M. (2001) Glycopeptide analgesics. Drugs Future 26, 561–576.
83. Asahi, S., Egashira, S., Matsuda, M., et al. (2003) Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B. Bioorg. Med. Chem. Lett. 13, 111–113.
84. Asahi, S., Egashira, S., Matsuda, M., et al. (2000) Structure-activity relationship studies on the novel neuropeptide orexin. The Japanese Peptide Society.
85. Darker, J.G., Porter, R.A., Eggleston, D.S., et al. (2001) Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg. Med. Chem. Lett. 11, 737–740.
86. Lang, M., Soll, R.M., Durrenberger, F., Dautzenberg, F.M., and Beck-Sickinger A.G. (2004) Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J. Med. Chem. 47, 1153–1160.
87. Egleton, R.D. and Davis, T.P. (1997) Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 18, 1431–1439.
88. Wheatley, M., Hawtin, S.R., Wesley, V.J., et al. (2003) Agonist binding to peptide hormone receptors. Biochem. Soc. Trans. 31, 35–39.
89. Smart, D., Sabido-David, C., Brough, S.J., et al. (2001) SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. 132, 1179–1182.
90. Porter, R.A., Chan, W.N., Coulton, S., et al. (2001) 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg. Med. Chem. Lett. 11, 1907–1910.
91. Langmead, C.J., Jerman, J.C., Brough, S.J., Scott, C., Porter, R.A., and Herdon, H.J. (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br. J. Pharmacol. 141, 340–346.
92. Shiba, T., Ozu, M., Yoshida, Y., Mignot, E., and Nishino, S. (2002) Hypocretin stimulates [(35)S]GTP gamma S binding in Hcrtr 2-transfected cell lines and in brain homogenate. Biochem. Biophys. Res. Commun. 294, 615–620.
93. Hirose, M., Egashira, S., Goto, Y., (2003) et al. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroiso-quinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg. Med. Chem. Lett. 13, 4497–4499.
94. McAtee, L.C., Sutton, S.W., Rudolph, D.A., et al. (2004) Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg. Med. Chem. Lett. 14, 4225–4229.
95. Jones, D.N., Gartlon, J., Parker, F., et al. (2001) Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity. Psychopharmacology (Berl) 153, 210–218.
96. Rodgers, R.J., Halford, J.C., Nunes de Souza, R.L., et al. (2001) SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur. J. Neurosci. 13, 1444–1452.
97. Haynes, A.C., Chapman, H., Taylor, C., et al. (2002) Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept 104, 153–159.
98. Smith, M.I., Piper, D.C., Duxon, M.S., and Upton N. (2003) Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci. Lett. 2003; 341, 256–258.
99. Kiwaki, K., Kotz, C.M., Wang, C., Lanningham-Foster, L., and Levine, J.A. (2004) Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in rats. Am. J. Physiol. Endocrinol. Metab. 286, E551–E559.
100. Croston, G.E., Olsson, R., Currier, E.A., et al. (2002) Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)isochro-man-1-one (AC-7954). J. Med. Chem. 45, 4950–4953.
101. Zaveri, N. (2003) Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci. 73, 663–678.
102. Chackalamannil, S., Doller, D., Eagen, K., et al. (2001) Potent, low molecular weight thrombin receptor antagonists. Bioorg. Med. Chem. Lett. 11, 2851–2853.
103. Saar, K., Mazarati, A.M., Mahlapuu, R., et al. (2002) Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc. Natl. Acad. Sci. U S A 99, 7136–7141.
104. Frey, W.H., II, Liu, J., Chen, X., Thorne, R.G., Fawcett, J.R., and Ala, T.A. (1997) Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv. 4, 87–92.
105. Frey, W.H., II. (2002) Intranasal delivery: bypassing the blood–brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv. Technol. 2, 46–49.
106. Thorne, R.G. and Frey, W.H., 2nd. (2001) Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 40, 907–946.
107. Capsoni, S., Giannotta, S., and Cattaneo, A. (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. U S A 99, 12432–12437.
108. Jin, K., Xie, L., Childs, J., et al. (2003) Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann. Neurol. 53, 405–409.
109. Born, J., Lange, T., Kern, W., McGregor, G.P., Bickel, U., and Fehm, H.L. (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5, 514–516.
110. Hanson, L.R., Martinez, P.M., Taheri, S., Kamsheh, L., Mignot, E., and Frey, W.H., II. (2004) Intranasal administration of hypocretin 1 (Orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv. Technol. 4, 66–71.
111. Bjorklund, A. and Lindvall, O. (2000) Cell replacement therapies for central nervous system disorders. Nat. Neurosci. 3, 537–544.
112. Bjorklund, A. and Stenevi, U. (1979) Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 177, 555–560.
113. Bjorklund, A. and Stenevi, U. (1984) Intracerebral neural implants: neuronal replacement and reconstruction of damaged circuitries. Annu. Rev. Neurosci. 7, 279–308.
114. Drucker-Colin, R., Aguilar-Roblero, R., Garcia-Hernandez, F., Fernandez-Cancino, F., and Bermudez Rattoni, F. (1984) Fetal suprachiasmatic nucleus transplants: diurnal rhythm recovery of lesioned rats. Brain Res. 311, 353–357.
115. Koutouzis, T.K., Emerich, D.F., Borlongan, C.V., Freeman, T.B., Cahill, D.W., and Sanberg, P.R. (1994) Cell transplantation for central nervous system disorders. Crit. Rev. Neurobiol. 8, 125–162.
116. Perlow, M.J., Freed, W.J., Hoffer, B.J., Seiger, A., Olson, L., and Wyatt, R.J. (1979) Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204, 643–647.
117. Roitberg, B., Urbaniak, K., and Emborg, M. (2004) Cell transplantation for Parkinson’s disease. Neurol. Res. 26, 355–362.
118. Arias-Carrion, O., Murillo-Rodriguez, E., Xu, M., et al. (2004) Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 27, 1465–1470.
119. Bjorklund, A. (1993) Neurobiology. Better cells for brain repair. Nature 362, 414–415.
120. Bjorklund, L.M., Sanchez-Pernaute, R., Chung, S., et al. (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. U S A 99, 2344–2349.
121. Rossi, F. and Cattaneo, E. (2002) Opinion: neural stem cell therapy for neurological diseases: dreams and reality. Nat. Rev. Neurosci. 3, 401–409.
122. Wagner, J., Akerud, P., Castro, D.S., et al. (1999) Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat. Biotechnol. 17, 653–659.
123. Martinez-Serrano, A., Lundberg, C., Horellou, P., et al. (1995) CNS-derived neural progenitor cells for gene transfer of nerve growth factor to the adult rat brain: complete rescue of axo-tomized cholinergic neurons after transplantation into the septum. J. Neurosci. 15, 5668–5680.
124. Lundberg, C., Horellou, P., Mallet, J., and Bjorklund, A. (1996) Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Exp. Neurol. 139, 39–53.
125. Fisher, L.J., Jinnah, H.A., Kale, L.C., Higgins, G.A., and Gage, F.H. (1991) Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6, 371–380.
126. Andsberg, G., Kokaia, Z., Bjorklund, A., Lindvall, O., and Martinez-Serrano, A. (1998) Amelioration of ischaemia-induced neuronal death in the rat striatum by NGF-secreting neural stem cells. Eur. J. Neurosci. 10, 2026–2036.
127. Jakobsson, J., Rosenqvist, N., Thompson, L., Barraud, P., and Lundberg, C. (2004) Dynamics of transgene expression in a neural stem cell line transduced with lentiviral vectors incorporating the cHS4 insulator. Exp. Cell Res. 298, 611–623.
128. St George, J.A. (2003) Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 10, 1135–1141.
129. Snyder, R.O. (1999) Adeno-associated virus-mediated gene delivery. J. Gene Med. 1, 166–175.
130. Russell, D.W. and Kay, M.A. (1999) Adeno-associated virus vectors and hematology. Blood 94, 864–874.
131. Monahan, P.E. and Samulski, R.J. (2000) AAV vectors: is clinical success on the horizon? Gene Ther. 7, 24–30.
132. Flotte, T.R. (2004) Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 11, 805–810.
133. Delenda, C. (2004) Lentiviral vectors: optimization of packaging, transduction and gene expression. J. Gene Med. 6(suppl 1), S125–S138.
134. Daly, G. and Chernajovsky, Y. (2000) Recent developments in retroviral-mediated gene transduction. Mol. Ther. 2, 423–434.
135. Brustle, O., Maskos, U., and McKay, R.D. (1995) Host-guided migration allows targeted introduction of neurons into the embryonic brain. Neuron 15, 1275–1285.
136. Campbell, K., Olsson, M., and Bjorklund, A. (1995) Regional incorporation and site-specific differentiation of striatal precursors transplanted to the embryonic forebrain ventricle. Neuron 15, 1259–1273.
137. Fishell, G. (1995) Striatal precursors adopt cortical identities in response to local cues. Development 121, 803–812.
138. Fricker, R.A., Carpenter, M.K., Winkler, C., Greco, C., Gates, M.A., and Bjorklund, A. (1999) Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J. Neurosci. 19, 5990–6005.
139. Asahara, T., Kalka, C., and Isner, J.M. (2000) Stem cell therapy and gene transfer for regeneration. Gene Ther. 7, 451–457.